Insulet Stock (PODD)

XNGS Alert Compare

Health Care · Fundamental analysis

· How we analyze

Metrics from daily candles, as of Nov 20, 2026 · Extended universe

Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year

Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Academy: 200-day line · RSI

About the company

Insulet is a US medical technology company. It makes the Omnipod insulin pump, a tubeless pump worn directly on the skin that makes insulin delivery easier for people with diabetes. It sells mainly in the US and Europe. As of Oct 11, 2026

Fact sheet (from the annual report) Medical instruments · Acton, USA

Insulet primarily develops, manufactures and sells its own systems for continuous insulin delivery for people with insulin-requiring diabetes. The Omnipod platform includes Omnipod 5 with a built-in control algorithm and Omnipod DASH, each with a self-adhesive, tubeless disposable pod. In August 2024 Omnipod 5 received an expanded FDA clearance for adults with type 2 diabetes. In the US, the company supplies wholesalers for the pharmacy channel and also delivers through distribution partners and directly to consumers. It also makes pods for Amgen, which are used in the delivery system for the drug Neulasta.

Automatically summarized from SEC annual report (10-K, filed Feb 18, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 15, 2026

Price performance at a glance

Last 30 trading days
  • Today −3.0%
  • 7 days −12.7%
  • 30 days −6.2%
  • 1 year −57.4%
Day range (last trading day)
−0.6%Price at 10% of the range+5.5%
52-week range
−5.1%Price at 3% of the range+156.9%
Distance from the all-time high
−62.5%

Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Fundamentals · Analysis method

Growth, margin, balance sheet, cash flow and dividend compared with the sector – with traffic lights and quality checks in the fundamental analysis. To the fundamental analysis

Fundamental analysis

Insulet Corporation · Sector Health Care · amounts in USD

Source: SEC filings, As of Feb 18, 2026.

For you first Dividend

The company pays no dividend.

For you first Valuation

The P/E is below its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

For you first Growth

How strongly revenue and earnings per share have grown over the years.

Check “Growth”
7 of 7
criteria with data met
Revenue per year (5 y)
+24.5%
EPS per year (5 y)
+103.4%

For you first Quality

How much of revenue remains and whether profit arrives as cash.

Check “Quality”
7 of 8
criteria with data met
Net margin
9.1%
Cash flow ÷ profit
2.30x
backed from 1.0 · 3 years: 1.31x

For you first Trading

The overview of this stock shows the trend by timeframe.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality 7 of 8 met

  • met: Gross margin above 40% 71.6%
  • met: Operating margin above 15% 17.5%
  • not met: Net margin above 10% 9.1%
  • met: Return on equity above 15% 16.3%
  • met: Free cash flow margin above 10% 13.9%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • met: Equity ratio above 30% 47.5%
Gross margin

71.6% Fiscal year 2025

Rank 85 of 100: higher than 85% of 370 peers (All). strong.

Rank 79 of 100: higher than 79% of 49 peers (Sector). strong.

Median Health Care: 61.8%

Share of revenue left after the direct cost of the products sold.

Operating margin

17.5% Fiscal year 2025

Rank 55 of 100: higher than 55% of 470 peers (All). medium.

Rank 53 of 100: higher than 53% of 54 peers (Sector). medium.

Median Health Care: 17.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

9.1% Fiscal year 2025

Rank 40 of 100: higher than 40% of 584 peers (All). medium.

Rank 42 of 100: higher than 42% of 63 peers (Sector). medium.

Median Health Care: 12.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

16.3% Fiscal year 2025

Rank 58 of 100: higher than 58% of 544 peers (All). medium.

Rank 64 of 100: higher than 64% of 54 peers (Sector). medium.

Median Health Care: 12.8%

Net income divided by equity at fiscal year end.

Return on assets

7.7% Fiscal year 2025 (total assets at year end)

Rank 67 of 100: higher than 67% of 594 peers (All). strong.

Rank 60 of 100: higher than 60% of 63 peers (Sector). medium.

Median Health Care: 6.6%

Net income divided by total assets at fiscal year end.

Equity ratio

47.5% Fiscal year 2025

Rank 67 of 100: higher than 67% of 595 peers (All). strong.

Rank 60 of 100: higher than 60% of 63 peers (Sector). medium.

Median Health Care: 44.2%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

13.9% Fiscal year 2025

Rank 57 of 100: higher than 57% of 465 peers (All). medium.

Rank 47 of 100: higher than 47% of 61 peers (Sector). medium.

Median Health Care: 14.5%

Free cash flow divided by revenue.

Free cash flow

377.7M USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 7 of 7 met

  • met: Over 3 years, revenue grew by more than 5% per year +27.5%
  • met: Over 5 years, revenue grew by more than 5% per year +24.5%
  • met: Over 10 years, revenue grew by more than 5% per year +26.2%
  • met: Over 3 years, EPS grew by more than 5% per year +267.7%
  • met: Over 5 years, EPS grew by more than 5% per year +103.4%
  • met: Revenue rose in at least 4 of the last 5 fiscal years 5 of 5
  • met: Revenue rose in the last fiscal year +30.7%
Revenue growth 3 years

+27.5% per year

Rank 90 of 100: higher than 90% of 578 peers (All). strong.

Rank 96 of 100: higher than 96% of 62 peers (Sector). strong.

Median Health Care: +5.1%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+24.5% per year

Rank 86 of 100: higher than 86% of 549 peers (All). strong.

Rank 98 of 100: higher than 98% of 60 peers (Sector). strong.

Median Health Care: +7.8%

Average growth per year over 5 fiscal years.

Revenue growth 10 years

+26.2% per year

Rank 94 of 100: higher than 94% of 412 peers (All). strong.

Rank 91 of 100: higher than 91% of 50 peers (Sector). strong.

Median Health Care: +9.3%

Average growth per year over 10 fiscal years.

EPS growth 3 years

+267.7% per year

Rank 100 of 100: higher than 100% of 437 peers (All). strong.

Rank 99 of 100: higher than 99% of 54 peers (Sector). strong.

Median Health Care: +5.0%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

+103.4% per year

Rank 98 of 100: higher than 98% of 399 peers (All). strong.

Rank 97 of 100: higher than 97% of 47 peers (Sector). strong.

Median Health Care: +8.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 0 of 1 met · 6 without data

  • not met: Pays a dividend no dividend per share reported for the last fiscal year
  • no data: Payout ratio at most 60% of earnings pays no dividend
  • no data: Dividend paid in each of the last 5 fiscal years pays no dividend
  • no data: Dividend per share never lowered in the last 5 fiscal years pays no dividend
  • no data: Dividend per share higher than 5 years ago pays no dividend
  • no data: Free cash flow per share covers the dividend pays no dividend
  • no data: Dividends paid over the last 5 years covered by free cash flow pays no dividend

Financial strength 5 of 6 met

  • met: Piotroski F-Score at least 7 of 9 7 of 9
  • met: Long-term debt no higher than equity 0.63
  • met: Current assets cover current liabilities 2.81
  • met: Positive equity 1.5B USD
  • not met: In 5 years, share count up by at most 5% +9.0%
  • met: Free cash flow positive in the last fiscal year 377.7M USD
Piotroski F-Score

7 of 9 Fiscal year 2025

Rank 69 of 100: higher than 69% of 310 peers (All). strong.

Rank 65 of 100: higher than 65% of 47 peers (Sector). medium.

Median Health Care: 6.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

0.63 at fiscal year end

Rank 52 of 100: lower than 52% of 486 peers (All). medium.

Rank 53 of 100: lower than 53% of 50 peers (Sector). medium.

Median Health Care: 0.66

Long-term financial debt divided by equity.

Liquidity (current ratio)

2.81 at fiscal year end

Rank 83 of 100: higher than 83% of 513 peers (All). strong.

Rank 79 of 100: higher than 79% of 63 peers (Sector). strong.

Median Health Care: 1.58

Current assets divided by current liabilities.

Change in share count

+9.0% in 5 years

Rank 21 of 100: lower than 21% of 507 peers (All). weak.

Rank 6 of 100: lower than 6% of 59 peers (Sector). weak.

Median Health Care: −4.3%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • not met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • met: Long-term debt relative to total assets fell
  • not met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • met: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light green: Revenue grew over 5 years (+24.5% per year), at least as fast as the sector median.
  • Light green: Net income (total) grew over 5 years (+105.2% per year), at least as fast as the sector median; per share +103.4% per year.
  • Light yellow: Net margin 9.1%, below the sector median (13.9%).
  • Light green: Debt not higher than usual in the sector.
  • Light red: Profit in 8 of 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 367.0M USD · Net income −28.9M USD · Net margin −7.9%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 463.8M USD · Net income −26.8M USD · Net margin −5.8%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 563.8M USD · Net income 3.3M USD · Net margin 0.6%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 738.2M USD · Net income 11.6M USD · Net margin 1.6%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 904.4M USD · Net income 6.8M USD · Net margin 0.8%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 1.1B USD · Net income 16.8M USD · Net margin 1.5%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 1.3B USD · Net income 4.6M USD · Net margin 0.4%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 1.7B USD · Net income 206.3M USD · Net margin 12.2%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 2.1B USD · Net income 418.3M USD · Net margin 20.2%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 2.7B USD · Net income 247.1M USD · Net margin 9.1%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 2.7B USD · Net income 247.1M USD · Net margin 9.1%

How has it gone since the last annual report?

Trailing 12 months and quarters

Revenue in the quarter to Sep 2026 +19.2% vs. the same quarter a year earlier; grown for at least 16 quarters in a row.

Revenue 12 months vs. prior 12
+26.5%
12 months: 3.2B USD · Fiscal year 2025: +30.7%
Net margin 12 months
13.4%
Fiscal year 2025: 9.1%
Free cash flow margin 12 months
8.2%
Fiscal year 2025: 13.9%
More depth

Calculation of the 12 months to Sep 30, 2026

  • Revenue: fiscal year to Dec 31, 2025 2.7B USD + year to date to Sep 30, 2026 2.4B USD − same period a year earlier to Sep 30, 2025 1.9B USD = 3.2B USD
  • Net income: fiscal year to Dec 31, 2025 247.1M USD + year to date to Sep 30, 2026 327.1M USD − same period a year earlier to Sep 30, 2025 145.5M USD = 428.7M USD
  • Operating cash flow: fiscal year to Dec 31, 2025 569.3M USD + year to date to Sep 30, 2026 325.7M USD − same period a year earlier to Sep 30, 2025 386.0M USD = 509.0M USD
  • Capital expenditure: fiscal year to Dec 31, 2025 191.6M USD + year to date to Sep 30, 2026 113.9M USD − same period a year earlier to Sep 30, 2025 56.5M USD = 249.0M USD
By quarter (latest first, amounts in USD)
QuarterRevenuevs. year agoNet incomeMargin
Jul–Sep 26842.0M+19.2%141.1M16.8%
Apr–Jun 26801.7M+23.5%95.0M11.8%
Jan–Mar 26761.7M+33.9%91.1M12.0%
Oct–Dec 25*783.8M+31.2%101.6M13.0%
Jul–Sep 25706.3M+29.9%87.6M12.4%
Apr–Jun 25649.1M+32.9%22.5M3.5%
Jan–Mar 25569.0M+28.8%35.4M6.2%
Oct–Dec 24*597.5M+17.2%100.7M16.9%

Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.

Each quarter is compared with the same quarter a year earlier.

* derived: fiscal year minus the first 9 months.

As of: 12 months to Sep 30, 2026, filed on Nov 4, 2026 · Source: SEC filings (10-Q, 10-K)

Does the profit arrive as cash?

Earnings quality

Profit is backed by cash; interest is well covered.

Cash flow ÷ profit
2.30x
backed from 1.0 · 3 years: 1.31x
Interest coverage
8.0x
well covered from 5 · 3 years: 7.3x
Tax rate
27.2%
for information only · 3 years: −2.0%
More depth

Calculation for fiscal year 2025

  • Operating cash flow 569.3M USD ÷ Net income 247.1M USD = 2.30x
  • Operating income 473.8M USD ÷ Interest expense 59.4M USD = 8.0x
  • Taxes 92.4M USD ÷ profit before tax 339.5M USD = 27.2%
By fiscal year
FYCash flow ÷ profitInterest coverageTax rate
20252.30x8.0x27.2%
20241.03x7.2x−39.3%
20230.71x6.1x3.9%
2022over 10x1.0x53.1%
2021negative2.0x18.0%

How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.

Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.

As of fiscal year 2025 · Source: SEC filings

How even were the last years?

Consistency

In 10 fiscal years 2 loss years and no year with lower revenue.

Loss years
2 of 10
net income below zero
Years with lower revenue
0 of 10
revenue below the prior year
Net margin range
28.1 percentage points
from −7.9% to 20.2%
Net margin by fiscal year
More depth
By fiscal year
FYRevenue vs. prior yearNet margin
2025+30.7%9.1%
2024+22.1%20.2%
2023+30.0%12.2%
2022+18.8%0.4%
2021+21.5%1.5%
2020+22.5%0.8%
2019+30.9%1.6%
2018+21.6%0.6%
2017+26.4%−5.8%
2016+39.1%−7.9%

Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.

As of fiscal years 2016–2025 · Source: SEC filings

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 71.6 USD gross profit, 17.5 USD operating income and 9.1 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue2.7B USD100.0%
Gross profit1.9B USD71.6%
Cost of revenue768.2M USD28.4%
Operating income473.8M USD17.5%
Research & development301.1M USD11.1%
Other operating expenses1.2B USD43.0%
Net income247.1M USD9.1%
Interest expense59.4M USD2.2%
Taxes92.4M USD3.4%
Other74.9M USD2.8%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin rose in 5 years from 5.7% to 17.5%.

Gross marginOperating marginNet margin
  1. Fiscal year 2016: Gross margin 57.5% · Operating margin −2.9% · Net margin −7.9%
  2. Fiscal year 2017: Gross margin 59.8% · Operating margin −1.6% · Net margin −5.8%
  3. Fiscal year 2018: Gross margin 65.7% · Operating margin 4.9% · Net margin 0.6%
  4. Fiscal year 2019: Gross margin 65.1% · Operating margin 6.8% · Net margin 1.6%
  5. Fiscal year 2020: Gross margin 64.4% · Operating margin 5.7% · Net margin 0.8%
  6. Fiscal year 2021: Gross margin 68.4% · Operating margin 11.5% · Net margin 1.5%
  7. Fiscal year 2022: Gross margin 61.7% · Operating margin 2.9% · Net margin 0.4%
  8. Fiscal year 2023: Gross margin 68.3% · Operating margin 13.0% · Net margin 12.2%
  9. Fiscal year 2024: Gross margin 69.8% · Operating margin 14.9% · Net margin 20.2%
  10. Fiscal year 2025: Gross margin 71.6% · Operating margin 17.5% · Net margin 9.1%

Returns

Return on equity rose in 5 years from 1.1% to 16.3%.

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity −45.7% · Return on assets −6.3%
  2. Fiscal year 2017: Return on equity −16.9% · Return on assets −3.3%
  3. Fiscal year 2018: Return on equity 1.6% · Return on assets 0.4%
  4. Fiscal year 2019: Return on equity 15.3% · Return on assets 1.0%
  5. Fiscal year 2020: Return on equity 1.1% · Return on assets 0.4%
  6. Fiscal year 2021: Return on equity 3.0% · Return on assets 0.8%
  7. Fiscal year 2022: Return on equity 1.0% · Return on assets 0.2%
  8. Fiscal year 2023: Return on equity 28.2% · Return on assets 8.0%
  9. Fiscal year 2024: Return on equity 34.5% · Return on assets 13.5%
  10. Fiscal year 2025: Return on equity 16.3% · Return on assets 7.7%

Equity and long-term debt

The equity ratio rose in 5 years from 32.2% to 47.5%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases. Definition changes: some years use a different debt tag.
  1. Fiscal year 2016: Equity 63.2M USD · Long-term debt 332.8M USD
  2. Fiscal year 2017: Equity 158.5M USD · Long-term debt 566.2M USD
  3. Fiscal year 2018: Equity 212.1M USD · Long-term debt 592.0M USD
  4. Fiscal year 2019: Equity 75.9M USD · Long-term debt 887.9M USD
  5. Fiscal year 2020: Equity 603.6M USD · Long-term debt 1.1B USD
  6. Fiscal year 2021: Equity 556.3M USD · Long-term debt 1.3B USD
  7. Fiscal year 2022: Equity 476.4M USD · Long-term debt 1.4B USD
  8. Fiscal year 2023: Equity 732.7M USD · Long-term debt 1.4B USD
  9. Fiscal year 2024: Equity 1.2B USD · Long-term debt 1.4B USD
  10. Fiscal year 2025: Equity 1.5B USD · Long-term debt 949.2M USD

Liquidity (current ratio)

The current ratio fell in 5 years from 6.01 to 2.81.

Current ratio
  1. Fiscal year 2016: Current ratio 6.64
  2. Fiscal year 2017: Current ratio 6.24
  3. Fiscal year 2018: Current ratio 3.99
  4. Fiscal year 2019: Current ratio 3.75
  5. Fiscal year 2020: Current ratio 6.01
  6. Fiscal year 2021: Current ratio 5.81
  7. Fiscal year 2022: Current ratio 3.60
  8. Fiscal year 2023: Current ratio 3.51
  9. Fiscal year 2024: Current ratio 3.58
  10. Fiscal year 2025: Current ratio 2.81

Cash flow

Free cash flow rose in 5 years from −45.0M USD to 377.7M USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 15.9M USD · Capital expenditure 22.1M USD · Free cash flow −6.2M USD
  2. Fiscal year 2017: Operating cash flow 41.2M USD · Capital expenditure 77.2M USD · Free cash flow −36.0M USD
  3. Fiscal year 2018: Operating cash flow 35.9M USD · Capital expenditure 162.4M USD · Free cash flow −126.5M USD
  4. Fiscal year 2019: Operating cash flow 98.4M USD · Capital expenditure 163.7M USD · Free cash flow −65.3M USD
  5. Fiscal year 2020: Operating cash flow 84.0M USD · Capital expenditure 129.0M USD · Free cash flow −45.0M USD
  6. Fiscal year 2021: Operating cash flow −68.1M USD · Capital expenditure 111.9M USD · Free cash flow −180.0M USD
  7. Fiscal year 2022: Operating cash flow 119.0M USD · Capital expenditure 122.9M USD · Free cash flow −3.9M USD
  8. Fiscal year 2023: Operating cash flow 145.7M USD · Capital expenditure 75.6M USD · Free cash flow 70.1M USD
  9. Fiscal year 2024: Operating cash flow 430.3M USD · Capital expenditure 124.9M USD · Free cash flow 305.4M USD
  10. Fiscal year 2025: Operating cash flow 569.3M USD · Capital expenditure 191.6M USD · Free cash flow 377.7M USD

Share count

The share count rose in 5 years by 9.0% – more new shares were issued than repurchased (dilution).

Diluted share count
  1. Fiscal year 2016: Diluted share count 57.3M
  2. Fiscal year 2017: Diluted share count 58.0M
  3. Fiscal year 2018: Diluted share count 61.0M
  4. Fiscal year 2019: Diluted share count 62.3M
  5. Fiscal year 2020: Diluted share count 65.9M
  6. Fiscal year 2021: Diluted share count 68.6M
  7. Fiscal year 2022: Diluted share count 69.9M
  8. Fiscal year 2023: Diluted share count 73.6M
  9. Fiscal year 2024: Diluted share count 73.9M
  10. Fiscal year 2025: Diluted share count 71.9M

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Metrics chart

Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.

Metrics, up to 3 – to switch, deselect one first

Premium Line of a second stock for comparison

Net margin

The net margin rose in 5 years from 0.8% to 9.1%.

PODD Sector today 13.2% Mark in the latest year: today’s median of the Health Care sector as in the sector comparison (each latest fiscal year). We do not have earlier medians.
  1. Fiscal year 2016: PODD −7.9%
  2. Fiscal year 2017: PODD −5.8%
  3. Fiscal year 2018: PODD 0.6%
  4. Fiscal year 2019: PODD 1.6%
  5. Fiscal year 2020: PODD 0.8%
  6. Fiscal year 2021: PODD 1.5%
  7. Fiscal year 2022: PODD 0.4%
  8. Fiscal year 2023: PODD 12.2%
  9. Fiscal year 2024: PODD 20.2%
  10. Fiscal year 2025: PODD 9.1% · Sector today 13.2%

Return on equity

Return on equity rose in 5 years from 1.1% to 16.3%.

PODD Sector today 14.3%
  1. Fiscal year 2016: PODD −45.7%
  2. Fiscal year 2017: PODD −16.9%
  3. Fiscal year 2018: PODD 1.6%
  4. Fiscal year 2019: PODD 15.3%
  5. Fiscal year 2020: PODD 1.1%
  6. Fiscal year 2021: PODD 3.0%
  7. Fiscal year 2022: PODD 1.0%
  8. Fiscal year 2023: PODD 28.2%
  9. Fiscal year 2024: PODD 34.5%
  10. Fiscal year 2025: PODD 16.3% · Sector today 14.3%

Free cash flow margin

The free cash flow margin rose in 5 years from −5.0% to 13.9%.

PODD Sector today 14.7%
  1. Fiscal year 2016: PODD −1.7%
  2. Fiscal year 2017: PODD −7.8%
  3. Fiscal year 2018: PODD −22.4%
  4. Fiscal year 2019: PODD −8.8%
  5. Fiscal year 2020: PODD −5.0%
  6. Fiscal year 2021: PODD −16.4%
  7. Fiscal year 2022: PODD −0.3%
  8. Fiscal year 2023: PODD 4.1%
  9. Fiscal year 2024: PODD 14.7%
  10. Fiscal year 2025: PODD 13.9% · Sector today 14.7%

Source: SEC filings, fiscal years up to Dec 31, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.

How reliable is the dividend?

Dividend at a glance

The company pays no dividend.

As of fiscal year 2025 · Source: SEC filings

Valued higher or lower than usual?

Valuation against its own history

The P/E is below its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

Source: SEC filings and our daily candles

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
none pays no dividend
To shareholders (3 years)
59.6M USD 100% through repurchases
Share count over 5 years
+9.0% more shares – dilution

What goes back to shareholders

Over 3 years, 59.6M USD went back to shareholders, 100% of it through share repurchases. That is 8% of the free cash flow of those years.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid not available · Share repurchases not available · New shares issued (including employee plans) 4.9M USD · Free cash flow −6.2M USD
  2. Fiscal year 2017: Dividends paid not available · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow −36.0M USD
  3. Fiscal year 2018: Dividends paid not available · Share repurchases not available · New shares issued (including employee plans) 0.0 USD · Free cash flow −126.5M USD
  4. Fiscal year 2019: Dividends paid not available · Share repurchases not available · New shares issued (including employee plans) 0.0 USD · Free cash flow −65.3M USD
  5. Fiscal year 2020: Dividends paid not available · Share repurchases not available · New shares issued (including employee plans) 477.5M USD · Free cash flow −45.0M USD
  6. Fiscal year 2021: Dividends paid not available · Share repurchases not available · New shares issued (including employee plans) 0.0 USD · Free cash flow −180.0M USD
  7. Fiscal year 2022: Dividends paid not available · Share repurchases not available · New shares issued (including employee plans) 0.0 USD · Free cash flow −3.9M USD
  8. Fiscal year 2023: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 70.1M USD
  9. Fiscal year 2024: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 305.4M USD
  10. Fiscal year 2025: Dividends paid not available · Share repurchases 59.6M USD · New shares issued (including employee plans) not available · Free cash flow 377.7M USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Insulet Corporation next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison PODD, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
SYK Stryker Corporation 25.1B USD +11.8%64.0%19.5%12.9%14.5%46.9%17.1%6/9
DHR Danaher Corporation 24.6B USD +2.0%59.1%19.1%14.7%6.9%62.9%21.4%7/9
REGN Regeneron Pharmaceuticals 14.3B USD +11.0%–24.9%31.4%14.4%77.1%28.4%–
VRTX Vertex Pharmaceuticals 12.0B USD +14.1%86.2%34.8%32.9%21.2%72.8%26.6%–
ISRG Intuitive Surgical 10.1B USD +18.2%66.0%29.3%28.4%16.0%87.1%24.7%–
PODD Insulet Corporation this stock 2.7B USD +24.5%71.6%17.5%9.1%16.3%47.5%13.9%7/9
MRNA Moderna 1.9B USD +19.3%55.3%−158.1%−145.2%−32.6%70.1%−106.2%2/9
NVAX Novavax 1.1B USD +18.8%93.5%40.3%39.2%–−10.9%−22.3%5/9
IOVA Iovance Biotherapeutics 263.5M USD –34.3%−153.1%−148.4%−56.0%76.5%−127.6%–
Median of the sector 27 symbols 44.3B USD +9.4%67.9%17.8%13.2%14.3%38.5%14.7%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Compare with the closest peer in the sector PODD next to MRNA – quality checks, metrics and depth side by side.

Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light green: above sector

+24.5% per year, last 5 years

Sector Health Care: median +8.5% (25 symbols)

What does this mean? Revenue: over 5 years it grew by 24.5% per year on average – at least as fast as the median company in the sector (+8.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light green: above sector

+105.2% per year, last 5 years

Sector Health Care: median +5.5% (20 symbols)

per share: +103.4% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it grew by 105.2% per year on average – at least as fast as the median company in the sector (+5.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light yellow: below sector

9.1% last fiscal year

Sector Health Care: median 13.9% (26 symbols)

What does this mean? Of every 100 USD in revenue, 9.12 USD remained as profit – less than the median company in the sector (13.9%). Five years ago the margin was 0.8%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light green: lower than sector

0.61 latest balance sheet

Sector Health Care: median 0.66 (19 symbols)

What does this mean? For every 1 USD of equity there is 0.61 USD of financial debt – no more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light gray: none found

– Dividend / earnings per share

Sector Health Care: median 56% (16 symbols)

What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light red: 2 loss years

8 of 10 fiscal years with a profit

What does this mean? In 8 of the last 10 fiscal years the bottom line showed a profit. 2 years ended with a loss.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
2.7B USD
Revenue vs. prior year
+30.7%
Net income (FY)
247.1M USD
Net income vs. prior year
−40.9%
EPS (FY)
3.48 USD
Superinvestors holding
3 of 26
Fiscal year to Dec 31, 2025 · 10-K filed Feb 18, 2026 · Balance sheet Sep 30, 2026 (filed Nov 4, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 2.7B247.1M 9.1% 3.48 – –
2024Dec 31, 2024 2.1B418.3M 20.2% 5.78 – –
2023Dec 31, 2023 1.7B206.3M 12.2% 2.94 – –
2022Dec 31, 2022 1.3B4.6M 0.4% 0.07 – –
2021Dec 31, 2021 1.1B16.8M 1.5% 0.24 – –
2020Dec 31, 2020 904.4M6.8M 0.8% 0.10 – –
2019Dec 31, 2019 738.2M11.6M 1.6% 0.19 – –
2018Dec 31, 2018 563.8M3.3M 0.6% 0.05 – –
2017Dec 31, 2017 463.8M−26.8M −5.8% −0.46 – –
2016Dec 31, 2016 367.0M−28.9M −7.9% −0.48 – –
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Sep 30, 2026 842.0M141.1M 16.8% 2.03 – –
Q2/26Jun 30, 2026 801.7M95.0M 11.8% 1.37 – –
Q1/26Mar 31, 2026 761.7M91.1M 12.0% 1.30 – –
Q4/25*Dec 31, 2025 783.8M101.6M 13.0% – – –
Q3/25Sep 30, 2025 706.3M87.6M 12.4% 1.24 – –
Q2/25Jun 30, 2025 649.1M22.5M 3.5% 0.32 – –
Q1/25Mar 31, 2025 569.0M35.4M 6.2% 0.50 – –
Q4/24*Dec 31, 2024 597.5M100.7M 16.9% – – –
Q3/24Sep 30, 2024 543.9M77.5M 14.2% 1.08 – –
Q2/24Jun 30, 2024 488.5M188.6M 38.6% 2.59 – –
Q1/24Mar 31, 2024 441.7M51.5M 11.7% 0.73 – –
Q4/23*Dec 31, 2023 509.8M103.3M 20.3% – – –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Information only – does not affect the other analysis methods, not investment advice.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $00 people $0
6 months $1.1M3 people $59.9K1 person +$1.0M
12 months $2.9M4 people $602.4K2 people +$2.3M

Latest transactions

  • Aug 21, 2026 McEvoy Ashley Chief executive (CEO), Director Open-market purchase 1,100 shares · $162.2K · SEC
  • Jun 3, 2026 Stonesifer Timothy C. Director Open-market purchase 2,790 shares · $400.4K · SEC
  • Jun 3, 2026 Borio Luciana Director Open-market sale 418 shares · $59.9K · SEC
  • Jun 3, 2026 Weatherman Elizabeth H Director Open-market purchase 3,450 shares · $497.5K · SEC
  • Feb 25, 2026 Minogue Michael R Director Open-market purchase 2,030 shares · $499.8K · SEC
  • Feb 20, 2026 McEvoy Ashley Chief executive (CEO), Director Open-market purchase 4,300 shares · $1.0M · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Which superinvestors hold Insulet Corporation?

All superinvestor portfolios

3 of 26 tracked superinvestors report a position.

Superinvestors with a position in Insulet Corporation, weight in each portfolio
InvestorWeight in portfoliovs. previous quarterAs of
Paul Tudor Jones Tudor Investment Corp 0.2% +113.9% increased Q3 2026
Renaissance Technologies < 0.1% +55.1% increased Q3 2026
Bridgewater Associates < 0.1% −47.0% reduced Q3 2026

Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

Trend score –

We do not calculate a trend score for symbols in the extended universe.

Volatility and trend strength

ADX 14 (trend strength)–
Price change 60 days–

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

No recent news found. News is loaded automatically three times a day for trend stocks, symbols with a current Elliott setup and favorites.

Posts

No posts on PODD yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: PODD

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly, stocks twice a day, precious metals every 4 hours on trading days, extended universe on weekdays after the close (daily candles) – not in real time.

↑ ↓ select · Enter open · Esc close